HIGHLIGHTS
- who: Christian Buske from the (UNIVERSITY) have published the Article: Managing Waldenstru00f6mu2812s macroglobulinemia with BTK inhibitors, in the Journal: (JOURNAL) of 19/Nov/2022
SUMMARY
The minority of patients with the MYD88WT genotype have a more aggressive disease than patients with mutated MYD88 and respond poorly to ibrutinib monotherapy. The efficacy of ibrutinib monotherapy in previously treated patients with WM was demonstrated in a pivotal phase II trial (NCT01614821) of 90.5% and 79.4%, respectively, at a median follow-up of 59 months. This study established ibrutinib as a highly active treatment . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.